Cancer drugs may get cheaper as govt set to cap trade margins at 30%
First reported 8 Oct, 10:44 UTCUpdated 3h ago9 sources
2 left · 4 center · 3 right · Full breakdown
Polyview Briefing
AI-generatedThe government plans to cap trade margins at 30% of the Maximum Retail Price (MRP) for non-scheduled anti-cancer drugs, which left-leaning outlets say will reduce mark-ups from current levels of 170% to 700%.
How the Left framed it
Left-leaning outlets emphasise the high current mark-ups, stating the intervention will cut prices by up to 70% of MRP and result in cumulative annual savings of ₹2,500 crore for patients.
How the Center framed it
Center outlets report the move follows recent questioning by the Supreme Court and note that prices may fall up to 70%.
How the Right framed it
Right-leaning outlets report the cap will apply to branded and generic, domestic and imported, patented and non-patented drugs, leading to cheaper prices.
What everyone reports
- The government is capping trade margins at 30% of MRP for non-scheduled anti-cancer drugs.
- The cap covers branded and generic, domestic and imported, patented and non-patented medicines.
- Prices for these drugs may fall by up to 70%.
- The move affects 110 non-scheduled anti-cancer drugs.
Where coverage differs
- Left-leaning outlets state the current average trade mark-up is around 170%, reaching 700% in some cases.
- Left-leaning outlets report the intervention will result in cumulative annual savings of ₹2,500 crore for patients.
- Center outlets report the move comes days after the Supreme Court questioned the Centre over pricing.
Written by AI from the headlines and excerpts of 9 outlets (Z.ai) on 8 Oct, 16:55 UTC. It can make mistakes — read the original reporting below. How briefings work
Compare the headlines
How outlets on each side framed it
New Delhi: The National Pharmaceutical Pricing Authority on Thursday announced capping the trade margin on the prices non-scheduled a nti-cancer drugs at 30 per cent , days after the Supreme Court came down heavily on hospitals and pharmaceutical industry for compelling the patients to pay exorbitant prices for these…
NEW DELHI: Cancer drugs will soon become cheaper as the centre is all set to announce capping trade margins at 30% over the cost to distributors. According to official sources, the move will mean that cancer drugs will see a 70% slash in retail prices. This will help bring down prices of 110 anti-cancer drugs…
The cap will cover branded and generic, domestic and imported, patented and non-patented anti-cancer drugs that are not part of the scheduled price-control list.
Full coverage
9 outlets — tap a headline to read it at the source
- Govt caps trade margins on non-scheduled anti-cancer drugs at 30% of MRP (opens The Times of India in a new tab)
- Centre caps margins on cancer drugs, prices may fall up to 70% (opens India Today in a new tab)
Centre caps margins on cancer drugs prices may fall up to
- Government caps mark-ups on anti-cancer drugs at 30% of MRP: Report (opens CNBC-TV18 in a new tab)
The government plans to limit mark-ups on 110 non-scheduled anti-cancer drugs to 30% of MRP, covering branded, generic, domestic and imported medicines.
- Cancer drugs may get cheaper as govt set to cap trade margins at 30% (opens Business Today in a new tab)
This comes days after the Supreme Court questioned the Centre over the pricing of cancer medicines
- Cancer drugs to get cheaper by up to 70% as govt fixes trade margin at 30% (opens DNA India in a new tab)
The cap will cover branded and generic, domestic and imported, patented and non-patented anti-cancer drugs that are not part of the scheduled price-control list.
- Anti-cancer drug prices to come down as govt caps trade margins at 30% (opens Deccan Herald in a new tab)
New Delhi: The National Pharmaceutical Pricing Authority on Thursday announced capping the trade margin on the prices non-scheduled a nti-cancer drugs at 30 per cent , days after the Supreme Court came down heavily on hospitals and pharmaceutical industry for compelling the patients to pay exorbitant prices for these…
- Cancer medicine prices may drop 70 per cent as government plans trade margin cap (opens India TV in a new tab)
Prices of several anti-cancer medicines may fall by up to 70 per cent as the government moves to cap trade margins at 30 per cent of the Maximum Retail Price (MRP) for non-scheduled anti-cancer drugs, according to official sources.
- Cancer drugs to get 70% cheaper as centre plans to cap trade margins (opens The New Indian Express in a new tab)
NEW DELHI: Cancer drugs will soon become cheaper as the centre is all set to announce capping trade margins at 30% over the cost to distributors. According to official sources, the move will mean that cancer drugs will see a 70% slash in retail prices. This will help bring down prices of 110 anti-cancer drugs…
- Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP (opens The Hindu in a new tab)
Average trade mark-up on these drugs now around 170%, reaching 700% in some cases; intervention to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients
